DaVita (BSP:DVAI34) 3-Year EPS without NRI Growth Rate : 6.30% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is DaVita 3-Year EPS without NRI Growth Rate?

DaVita's EPS without NRI for the three months ended in Dec. 2023 was R$9.16.

During the past 12 months, DaVita's average EPS without NRI Growth Rate was 48.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 6.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 15.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of DaVita was 117.40% per year. The lowest was -22.80% per year. And the median was 11.65% per year.

Competitive Comparison of DaVita's 3-Year EPS without NRI Growth Rate

For the Medical Care Facilities subindustry, DaVita's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita's 3-Year EPS without NRI Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where DaVita's 3-Year EPS without NRI Growth Rate falls into.

DaVita 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

DaVita (BSP:DVAI34) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

DaVita 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of DaVita's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita (BSP:DVAI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

DVA:USA TRL:Germany

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines